Immunotherapy and biomarkers: Developments in Combination Therapy for Cancer
Over the past few years, increasing evidence has supported the role of biomarkers in immunotherapy. Combination therapy - the use of a combination of products or modalities to treat cancer - is one way to use biomarkers to reveal the...
3 years agoImmunotherapy and biomarkers: Developments in Combination Therapy for Cancer
Over the past few years, increasing evidence has supported the role of biomarkers in immunotherapy. Combination therapy - the use of a combination of products or modalities to treat cancer - is one way to use biomarkers to reveal the...
3 years ago
Innovations in Oncology: An Interview with Raluca Budiu-Predoiu
“These are exciting times for all areas of oncology.” With new advances across the oncological board, from immuno-oncology and biomarkers, it is important to keep up with and understand the latest innovations. We spoke to Raluca Budiu-Predoiu, Translational Oncology Principal...
3 years agoInnovations in Oncology: An Interview with Raluca Budiu-Predoiu
“These are exciting times for all areas of oncology.” With new advances across the oncological board, from immuno-oncology and biomarkers, it is important to keep up with and understand the latest innovations. We spoke to Raluca Budiu-Predoiu, Translational Oncology Principal...
3 years ago
Broadening the Scope of Therapeutic Treatment – Advancements in Cancer Clinical Trials
With ground-breaking advancements in oncology like check-point inhibitors comes the extensive development of human clinical trials, prioritising patient safety and drug tolerability through pharmacovigilance. Proventa spoke to Chief Medical Officer for Xilio Therapeutics, Martin Huber, for his thoughts regarding exciting...
3 years agoBroadening the Scope of Therapeutic Treatment – Advancements in Cancer Clinical Trials
With ground-breaking advancements in oncology like check-point inhibitors comes the extensive development of human clinical trials, prioritising patient safety and drug tolerability through pharmacovigilance. Proventa spoke to Chief Medical Officer for Xilio Therapeutics, Martin Huber, for his thoughts regarding exciting...
3 years ago
Key Challenges in Oncology and Bioinformatics
This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Oncology/Bioinformatics events,...
4 years agoKey Challenges in Oncology and Bioinformatics
This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Oncology/Bioinformatics events,...
4 years ago
R&D: The Impact of AI in 2020
Whenever Proventa holds a Strategy Meeting around the world - regardless of meeting topic - the subject of AI comes up. It really is so important in pharma right now, with the potential to solve some of the sector's big...
4 years agoR&D: The Impact of AI in 2020
Whenever Proventa holds a Strategy Meeting around the world - regardless of meeting topic - the subject of AI comes up. It really is so important in pharma right now, with the potential to solve some of the sector's big...
4 years ago
Weekly News Round-up – 14/2/20
The U.S. Institute for Clinical and Economic Review’s (ICER’s) methods could see legal challenges in the near future, a think tank has warned, due to discrimination against disabled individuals. In other news, Novartis’ rare lung cancer drug capmatinib will be...
4 years agoWeekly News Round-up – 14/2/20
The U.S. Institute for Clinical and Economic Review’s (ICER’s) methods could see legal challenges in the near future, a think tank has warned, due to discrimination against disabled individuals. In other news, Novartis’ rare lung cancer drug capmatinib will be...
4 years ago
The Changing Role of the Blockbuster Drug
There are few pharmaceutical companies not seeking the next big "blockbuster", a market drug earning revenue over $1 billion. These big-name products, which include Keytruda and Lipitor, are well-marketed and broadly-effective, often across several illnesses. For years scientists have worked...
4 years agoThe Changing Role of the Blockbuster Drug
There are few pharmaceutical companies not seeking the next big "blockbuster", a market drug earning revenue over $1 billion. These big-name products, which include Keytruda and Lipitor, are well-marketed and broadly-effective, often across several illnesses. For years scientists have worked...
4 years ago
Weekly News Round-up – 17/1/20
The week passed fairly uneventfully this time, with the baffling politics and shocking events of the new decade struggling to get started. Instead, research from Scottish universities indicated a link between a type of common gut bacteria and Parkinson's; a...
4 years agoWeekly News Round-up – 17/1/20
The week passed fairly uneventfully this time, with the baffling politics and shocking events of the new decade struggling to get started. Instead, research from Scottish universities indicated a link between a type of common gut bacteria and Parkinson's; a...
4 years ago
The Future of Organ-on-a-Chip
Dozens of solutions have been suggested to lessen the crisis that has been hitting pharma R&D recently. Over the last decade, the cost of creating drugs has skyrocketed even as the amount of new medicines reaching market is steadily declining....
4 years agoThe Future of Organ-on-a-Chip
Dozens of solutions have been suggested to lessen the crisis that has been hitting pharma R&D recently. Over the last decade, the cost of creating drugs has skyrocketed even as the amount of new medicines reaching market is steadily declining....
4 years ago
Cancer Drugs Could be Hitting Wrong Targets
Current cancer drugs may be hitting the wrong protein targets, a study has found, giving a possible explanation for the low success rates of those drugs during their early stages. The study, recently published in Science Translational Medicine journal and...
5 years agoCancer Drugs Could be Hitting Wrong Targets
Current cancer drugs may be hitting the wrong protein targets, a study has found, giving a possible explanation for the low success rates of those drugs during their early stages. The study, recently published in Science Translational Medicine journal and...
5 years ago